RADIOMEDIX, INC.
212Pb-DOTAMTATE (AlphaMedix), a targeted alpha-emitter radiopharmaceutical for treating neuroendocrine tumors
- Sector
- Biotech
- Total capital
- $2M
- Federal grants
- $2M
- 2 awards · 2021–2022
- Rank in peer group#37 of 326
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $5K
- 1 award · Health and Human S
- Rank in Biotech#387 of 4373
- Granted patents
- 0
- 11 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Targeted alpha-emitter therapy of patients with PRRT refractory neuroendocrine tumors$1.5M
- Federal grantHealth and Human S · Phase II · Targeted alpha-emitter therapy of patients with PRRT refractory neuroendocrine tumors$548K
- Federal contractHealth and Human S · Igf::cl::igf Radiomedix, INC.:1238208 [pots: 15-016194]$5K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#37 · top 11%
- Linked publications#12 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 11- PendingAutomated Method And Device For Production Of Lead 212 For Use In Targeted Alpha-particle TherapyUSPTOApplication 19235565
- PendingAutomated Method And Device For Production Of Lead 212 For Use In Targeted Alpha-particle TherapyUSPTOApplication 18623611
- PendingComposition, Kit And Method For Diagnosis And Treatment Of Prostate CancerUSPTOApplication 17996958
Show all 11 patent records
- Automated Method And Device For Production Of Lead 212 For Use In Targeted Alpha-particle TherapyDec 4, 2025 · Application 19235565Pending
- Automated Method And Device For Production Of Lead 212 For Use In Targeted Alpha-particle TherapyOct 3, 2024 · Application 18623611Pending
- Composition, Kit And Method For Diagnosis And Treatment Of Prostate CancerMar 30, 2023 · Application 17996958Pending
- Compositions For Targeted Imaging And TherapyDec 29, 2016 · Application 15195334Pending
- Compositions, Methods Of Synthesis And Use Of Carbohydrate Targeted AgentsApplication PCTUS2012043255Pending
- Nanostructures Comprising Radioisotopes And/or MetalsApplication PCTUS2011049119Pending
- Radiolabeled Hedgehog Derivatives For Imaging And TherapyApplication PCTUS2009035489Pending
- Compositions For Targeted Imaging And TherapyApplication PCTUS2008058476Pending
- Automated Method And Device For Production Of Lead 212 For Use In Targeted Alpha-particle TherapyApplication PCTUS2024022482Pending
- Automated Method And Device For Production Of Lead 212 For Use In Targeted Alpha-particle TherapyApplication 63493139Pending
- Composition, Kit And Method For Diagnosis And Treatment Of Prostate CancerApplication PCTUS2021029124Pending
Recent research by its founders
- Abstract 3859: Dynamic systemic immune modulation in metastatic neuroendocrine tumor (NET) patients treated with targeted alpha-emitter212Pb-DOTAMTATE AlphaMedix.20260 cites
- Long-term Follow-up of PRRT-Naive Patients with GEP-NETs Treated with Targeted Alpha Therapy 212Pb-DOTAMTATE in the Phase 2 ALPHAMEDIX 02 Trial20260 cites
- Phase 2 Study of Targeted Alpha Therapy 212Pb-DOTAMTATE in Patients with Advanced Gastroenteropancreatic (GEP)-NETs Previously Treated with PRRT20260 cites
Related companies, and why
- Full Genomes CorpSimilar federal contract value in Biotech · $10K in contracts
- Cellecta, IncorporatedSimilar federal contract value in Biotech · $9K in contracts
- Zenobia Therapeutics, Inc.Similar federal contract value in Biotech · $8K in contracts
- STEALTH BIOLOGICS LLCSimilar federal contract value in Biotech · $5K in contracts
- Claret Bioscience LLCSimilar federal contract value in Biotech · $5K in contracts
- Minerva NeurosciencesSimilar federal contract value in Biotech · $5K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .